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Background. The electronic medical records provide new and unprecedented opportunities for large population-based and clinical
studies if valid and reliable diagnoses can be obtained, to determine what information is needed to distinguish idiopathic PD from
Parkinsonism in electronic medical records.Methods. Chart review of complete medical records of 2,446 patients with a hospital
discharge diagnosis of PD, who, between 1996 and 2009, were registered in the Danish National Hospital Register as idiopathic PD.
All patients were examined in neurology departments. Clinical features were abstracted from charts to determine Parkinsonian
phenotypes and disease course, using predefined criteria for idiopathic PD.Results. Chart review verified that 2,068 (84.5%) patients
met criteria for idiopathic PD.Themost distinguishing features of idiopathic PD patients were asymmetric onset, and fewer atypical
features at onset or follow-up compared to Parkinsonism, and the area under the curve (AUC) for these items alone is moderate
(0.74–0.77) and the highest AUC (0.91) was achieved when using all clinical features recorded in addition to PDmedication use and
a follow-up of 5 years or more. Conclusion. To reduce disease misclassification, information extracted from medical record review
with at least 5 years of follow-up after first diagnosis was key to improve diagnostic accuracy.
1. Introduction
Etiologic studies of idiopathic Parkinson’s disease (IPD) and
the identification of predictors of progression or severity
necessitate finding and following PD patients preferably
in a population-based manner. The growth of electronic
disease registration andmedical record systemsmay aid such
studies. However, establishing valid and reliable diagnoses is
a challenge since IPD shares symptoms with a number of
other diseases commonly referred to as Parkinsonism such as
atypical and secondary Parkinsonism [1]. Despite differences
in etiology and course of treatment these phenotypes are
not easily distinguishable from each other, especially early in
disease. To aid large scale, cost efficient, and timely medical
and pharmaceutical record-based studies of PD, we describe
here how—according to medical records from neurologic
departments in Denmark—clinical features develop over
time and may help in assessing the accuracy of an IPD
diagnosis [2, 3]. While the most definite IPD diagnosis
is made at autopsy, few patients are assessed postmortem
and almost all studies have to rely on clinical diagnoses
[1]. Clinicopathological studies suggested an error rate of
10–25% in diagnosing IPD with lower misdiagnosis among
movement disorder neurologists [4].
A classic study named the absence of atypical features,
asymmetric onset, and absence of listing of extraneous
causes for Parkinsonian syndromes as best predictors of
pathologically proven IPD [5]. Disease duration and respon-
siveness to PD medications have also been considered: using
a neuropathologic gold standard diagnostic accuracy of
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“responsiveness tomedication”was only 53% in early IPDand
increased to more than 85% after 5 years of disease duration
[6]. Two epidemiological studies in the United Kingdom
reported on the accuracy of IPD diagnoses in community-
based studies. In greater London, researchers screened med-
ical records from 15 general practices and for 202 PD patients
after review of the diagnosis was rejected for 15% [7]. Among
128 patients identified from general practitioners records in
Scotland, 11% received a revised diagnosis of essential tremor
and 8% of vascular Parkinsonism after clinical examination
[2].
Here we use data from the Danish health system to
evaluate diagnostic accuracy of electronic records with a pri-
mary ICD for IPD. Since 1 January 1977, the Danish National
Hospital Register (NHR) electronically records inpatient-
related services and diagnoses from all hospitals and for all
citizens using a unique Danish citizen identification number.
Outpatient contacts have been added since 1 January 1994 [8].
We screened theNHR for PD ICD codes as primary diagnosis
and retrieved medical records from neurology centers to
assess information on major symptoms and signs of PD
present at the time of diagnosis and at subsequent hospital
visits. In a pilot study, we previously reviewed records of 1,040
PD patients reported to the NHR and found that only 82%
suffered from IPD [9].We now present data for 2,446 patients
from 10major neurologic centers in Denmark with a primary
diagnosis of IPD from the NHR in 1996–2009 for whom
we collected baseline and follow-up information on clinical
PD features through a complete medical record review.
We evaluate how clinical features necessary for deriving an
IPD diagnosis are presented at onset and over time and,
for the first time, also describe treatment regimens and
compare comorbidities and vital status changes of patients
and compare those to population controls [10].
2. Material and Methods
We identified patients with a primary diagnosis of IPD
(ICD-8 code 342, ICD-10 code G20) at hospital discharge
age 35 or older from the Danish NHR between 1996 and
2009. At diagnosis, patients had to be 70 years of age or
less before 2002 and 80 years of age or less in 2002–2009
to ensure that most eligible patients survived to planned
interviews in 2007–2009 (for further details see [11]). To
increase diagnostic validity, only patients treated at any time
in 10 (𝑁 = 3,508) out of 15 major neurologic centers (𝑁 =
4,975) were eligible. We did not attempt to retrieve medical
charts for patients who died before contact for interview (𝑛 =
362), for whom a “research protection” prohibited contact
(𝑛 = 156), who lacked contact information (𝑛 = 110), or
were too ill to participate (𝑛 = 115) or unable to speak
English or Danish (𝑛 = 3). From among the 2,762 patients
left, we excluded 179 for whom an initial brief screening
of charts excluded IPD and 137 who refused interviews or
lacked medical records. In total 2,446 medical charts were
reviewed and signs and symptoms necessary to establish an
IPD diagnosis according to United Kingdom Brain Bank
and Gelb criteria abstracted [1, 12]; note that the first 1000
charts were retrieved and reviewed without consideration
of patient refusal of contact or death prior to interview [9].
The final diagnosis of treating neurologic specialists was
recorded, but wemade a diagnosis based on all of themedical
record information available and required the presence of
a minimum of two of the following symptoms: resting
tremor, bradykinesia, rigidity, and asymmetrical onset. We
also abstracted notes from private practitioners who often
treat patients before hospital/clinic admissions and reviewed
notes about treatment courses during inpatient stay or out-
patient clinic visits. We recorded age at first self-reported
symptom, patients’ response to treatment with levodopa,
signs of or test results for dementia, as well as early falls,
severe symptomatic dysautonomia, and sudden symptom
onset, supranuclear gaze palsy, hallucinations unrelated to
medication, freezing phenomena, Babinski’s sign, and symp-
toms for other brain/nervous system diseases, and records
for computed tomography scans, DaTSCANs, or magnetic
resonance scans. Almost all patient medical charts included
a computed tomography scan and/or a magnetic resonance
scan and 30% of records also contained a DaTSCAN and this
information was employed in the validation of the diagnosis.
We selected controls matched to cases on birth year and
gender.
To comparing cases according to clinical features, we
used chi-square tests and calculated for each the sensitivity,
specificity, and positive and negative predicted values for
a diagnosis of IPD. To determine the best combination of
IPD predictors, we plotted ROC curves and determined the
area under the curve (AUC) for four different prediction
models. Specifically, model 1 (full model) included all typ-
ical clinical and atypical features, asymmetrical onset, and
PD medication use listed in Table 4. The reduced model
2 includes only atypical features and one major cardinal
symptom: asymmetric onset. Model 3 (maximum atypical
features model) was restricted to atypical features only; and
model 4 (minimum atypical features model) dropped severe
autonomic dysfunction and supranuclear gaze palsy from
atypical features.
3. Results
Out of 2,446 patients with a primary IPD diagnosis, we
determined that 378 (15.5%) did not have IPD (compared
with 694 (25%) out of the initial 2,762 prior to initial record
screening), leaving 2,068 patients with IPD according to
our criteria and information provided in charts. Among the
378 cases who did not have IPD with a neurologic hospital
register based ICD code for PD there were 118 patients with
atypical PD (53 with LBD, 44 with MSA, and 21 with PSP
or CBD (tauopathies)), 125 with secondary or other types
of Parkinsonism, and 35 with essential tremor (ET) and 100
had an incomplete chart preventing us from establishing a
diagnosis. Out of 2,446 patients, 733 (30%) had received a
DaTSCAN that identified 131 as non-IPD even though they
were recorded as IPD in the NHR. Atypical and secondary
Parkinsonism patients while born earlier had later disease
onset; that is, they were older at time of diagnosis than IPD
patients and more likely to die between study enrolment and
end of follow-up (2007–2013) (Table 1).The three cardinal PD
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Figure 1: ROC curves for diagnosing iPD based on symptoms and
medications (ever listed in medical records).
signs (tremor, rigidity, and bradykinesia) and PDmedication
use frequencies at diagnosis did not differ between pheno-
types (50–60% prevalence). However, asymmetric onset was
recorded for a significantly higher proportion of IPD patients
(88.3% versus 64.3% non-IPD) (Table 2). During follow-up,
85–96% of all IPD patients developed the three cardinal signs
and 99% took PD medications, while 63–74% of non-IPD
patients developed these signs and only 80% received PD
medications.
More non-IPD (13.2%) than IPD (7.4%) patients took
antidepressant medication prior to or at diagnosis; there also
were large differences in comorbidities prior to diagnosis
(Table 3). Compared to population controls, a higher percent-
age of IPD patients suffered from heart disease, CVD, and
dementia but less had a COPD diagnosis. Clinical features
and PDmedication use within the first year of diagnosis, had
high sensitivity (66% to 89%) but low specificity even when
combining features (18% to 57%) (Table 4). Using all chart
information throughout follow-up (on average 6.6 years after
PDdiagnosis) theAUC for distinguishing IPD fromnon-IPD
was high (0.91) (Figure 1) but reduced to 0.82 when relying on
these features (from Table 4) observed within the first year of
diagnosis only and the AUC dropped to 0.68 or 0.69 in the
reduced model 3 or 4.
4. Discussion
Parkinson’s registries similar in coverage or accuracy to
cancer registries do not exist, but electronic medical records
hold promise for identifying IPD patients and would be
of great value for large scale population-based and clinical
studies. Few studies have described symptoms and pheno-
typic features of PD at onset and during progression in
a population-based sample [13, 14] and none is as large
a study as ours. Many clinical trials, etiologic studies, or
surveillance studies select patients early in disease to capture
incident patients and limit recall bias but are unable to
follow-up and reassess diagnoses over extended periods of
time. Identifying incident IPD cases shortly after diagnosis
even from neurologic centers invites misdiagnosis. Our data
suggest that at least 15–25% of IPD diagnoses based on ICD
codes early in disease are inaccurate, likely a conservative
estimate, since we only relied on neurologic speciality clinic
patients expected to have higher clinical accuracy [4]. This
is supported by data from a highly specialized tertiary care
clinic in the US, which reported that 8.1% of 800 patients
initially diagnosed with IPD were reclassified after 7.6 years
of follow-up [15]. A smaller study using neuropathologic
findings confirmed IPD in only 53% of cases within <5 years
of disease compared with >85% diagnostic accuracy after
longer disease duration [6].
General clinical wisdom holds that patients with IPD
more often experience tremor and asymmetric onset, while
atypical PD patients more often suffer from bradykinesia,
early falls, and severe dysautonomia, while secondary Parkin-
sonism might have sudden symptoms onset [1]. However,
our chart review showed that at diagnosis (or first visit
to a neurologic clinic reporting to the NHR) there was
no difference in the frequency of three cardinal symptoms,
postural instability was present in less than a quarter, and
atypical features were present in only 10-11% of all non-IPD
cases, confirming that based on clinical features, even in
neurologic centers, it is difficult tomake an accurate diagnosis
of IPD early in disease.
Moreover, many different forms of non-IPD Parkinson-
ism exist. For example, multiple systemic atrophy (MSA) is
known for dysautonomia and cerebellar and corticospinal
deficits [16, 17]. Patients with progressive supranuclear palsy
(PSP) show often symmetric onset with early falls, and
vertical supranuclear gaze palsy [18]. In dementia with Lewy
Body (LBD) cognitive impairment, often combining fluctu-
ating cognition and recurrent visual hallucinations, precedes
motor symptoms [16]. Corticobasal degeneration (CBD) is
difficult to clinically differentiate from other types of atyp-
ical Parkinsonism [19]. Secondary Parkinsonism includes
medication-induced or vascular syndromes. Vascular Parkin-
sonism may start abruptly with predominant lower body
involvement and postural instability [16] but might show in
neuroimaging. A recent study reported that out of 16 cases for
whom PD could not be confirmed neuropathologically one
had MSA and 7 PSP, 5 various neurodegenerative findings,
and 3 no findings to explain the Parkinsonism [6]. In sum,
while clinical features may distinguish IPD and atypical
and secondary PD in the long run, our data corroborate
the notion that differential diagnoses are not likely to be
accurate in the first 5 years after onset. More than half of
our patients had a PD ICD diagnosis in the NHR system
for more than 10 years at the time of chart review. When
relying solely on clinical diagnosis, it might be necessary
to abandon the emphasis on an early diagnosis to recruit
for incident studies or to conduct additional follow-up and
revise ICD classifications since additional features vastly
improve diagnostic accuracy. Of interest, patients for whom
our record review resulted in reclassifications to atypical or
secondary PD tended to be older and had more comorbid
diseases, and 74–100%of themdied during follow-up by 2013.
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Some countries have prescription drug databases avail-
able that offer the opportunity to identify PD patients for
studies. In our study, PD medications were consumed by
about half of all IPD and non-IPD patients at time of
diagnosis and almost 100% of IPD patients received PD
medications eventually, compared with 80% of non-IPD
patients. Hence, the best time to identify PD patients based
on medications alone might also be more than 5 years after
diagnosis, at which time 92% of IPD and 76% of non-
IPD patients have received some treatment and it can be
determined whether treatment was discontinued—a possible
indication of no benefit as seen for atypical Parkinson-
ism.
While levodopa is still the most commonly prescribed
medication, in Denmark many start treatment with a dopa-
agonist and/or MAO-B inhibitor first, likely due to rec-
ommendations for younger (<60 years) or less severe PD
patients to avoid levodopa-related motor complication [20].
Older patients with more atypical symptoms early on may
be started on levodopa supplemented with other medications
later. Lastly, patients with atypical PD may be responding
less to and receive smaller doses of levodopa [21]. Hence,
such treatment patterns could potentially aid in improv-
ing diagnostic accuracy for electronic record only based
studies.
A major and to date elusive goal of PD research is to
develop neuroprotective or disease-modifying therapies that
can stop or slow disease progression. Enrolling patients early
into trials leads to different phenotypes beingmixed together.
Nondopaminergic symptoms such as postural instability,
autonomic dysfunction, and dementia at diagnosis have
been considered main predictors of faster progression and
disability in the first five years of disease [14], but our data
demonstrate that these symptoms are observed in less than
50% of non-IPD patients and less than 20% of IPD cases
within 5 years of diagnosis. Improving diagnostic accuracy
based on medical record data is essential for future record
linkage studies to be useful in identifying new etiologic
factors and treatment modalities and for targeting disease
subtypes and progression.
In summary, our record review of patients with an ICD
code for IPD as a primary diagnosis in the Danish NHR
confirmed that only 75–85%of the patients originally selected
for study suffered from IPD. Thus, our data suggest that
electronic data sources need to be developed that provide
information not only on ICD codes but also on cardinal
and atypical symptoms, symmetry of onset, comorbidities,
and treatment modalities for all PD patients. To be most
informative in terms of predictive validity for IPD, these
data need to be used in combination and patients need to
be followed up over at least 5 years into disease to improve
diagnostic accuracy in studies that rely solely on record
linkage.
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